{"id":23453,"date":"2022-12-21T20:51:00","date_gmt":"2022-12-21T12:51:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23453"},"modified":"2025-01-27T20:54:50","modified_gmt":"2025-01-27T12:54:50","slug":"mabwell-bioscience-licenses-biosimilars-to-russian-firm-binnopharm","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23453","title":{"rendered":"Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm"},"content":{"rendered":"\n<p>China-based Mabwell Bioscience (<a href=\"https:\/\/www.google.com\/finance\/quote\/688062:SHA\">SHA: 688062<\/a>) has announced the establishment of a licensing agreement with the Russian pharmaceutical company Binnopharm Group, focused on 9MW0113, 9MW0321, and 9MW0311, Mabwell&#8217;s biosimilar versions of adalimumab and denosumab. Binnopharm will have exclusive rights to develop, register, manufacture, and market the drugs with a status of a local product in Russia and Eurasian Economic Union countries. Financial details of the agreement were not disclosed.<\/p>\n\n\n\n<p><strong>Biosimilar Products and Indications<\/strong><br>Mabwell&#8217;s 9MW0113 (Junmaikang), a biosimilar of Humira, has been approved in China for eight indications: rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn&#8217;s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children, and Crohn&#8217;s disease in children.<\/p>\n\n\n\n<p>9MW0321 is a proposed biosimilar of Xgeva (denosumab). Xgeva was approved for the indications of the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity; and the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.<\/p>\n\n\n\n<p>9MW0311 is a proposed biosimilar of Prolia (denosumab). Prolia was approved for the indications of the treatment of osteoporosis in women who have undergone menopause who have an increased risk for fractures or who cannot take or did not respond to other medication treatments for osteoporosis; treatment of men who have an increased risk for fractures or who cannot take or did not respond to other medication treatments for osteoporosis; treatment of osteoporosis that is caused by corticosteroid medications in men and women who will be taking corticosteroid medications for at least six months and have an increased risk for fractures, or who cannot take or did not respond to other medication treatments for osteoporosis; treatment of bone loss in men who are being treated for prostate cancer with certain medications that cause bone loss; and treatment of bone loss in women with breast cancer who are receiving certain medications that increase their risk for fractures.<\/p>\n\n\n\n<p><strong>Binnopharm Group Profile<\/strong><br>Binnopharm Group was founded through the consolidation of pharmaceutical assets of Sistema PJSFC (LSE: SSA, MOEX: AFKS) and is a top-five pharmaceutical company in Russia (according to AlphaRM) with a turnover of more than 25 billion Rubles. The firm is Russia\u2019s largest producer of generic medicines and the leading manufacturer of products intended for the Commonwealth of Independent States (CIS) markets. In 2020, Binnopharm became the first company in the world to manufacture a Covid-19 vaccine.<\/p>\n\n\n\n<p><strong>Mabwell Bioscience Profile<\/strong><br>Mabwell Bio is focused on the development of monoclonal antibodies, long-acting recombinant proteins, and other macromolecules, with a product pipeline consisting of upwards of 30 products and covering oncology, autoimmune disease, anti-infection, and eye diseases.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Mabwell Bioscience (SHA: 688062) has announced the establishment of a licensing agreement with the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,43,16,118,44,68,1129],"class_list":["post-23453","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-auto-immune","tag-biosimilars","tag-cancer","tag-mabwell-bioscience","tag-ophthalmology","tag-pediatric-drugs","tag-sha-688062"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Mabwell Bioscience (SHA: 688062) has announced the establishment of a licensing agreement with the Russian pharmaceutical company Binnopharm Group, focused on 9MW0113, 9MW0321, and 9MW0311, Mabwell&#039;s biosimilar versions of adalimumab and denosumab. Binnopharm will have exclusive rights to develop, register, manufacture, and market the drugs with a status of a local product in Russia and Eurasian Economic Union countries. Financial details of the agreement were not disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23453\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23453\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-21T12:51:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-27T12:54:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23453#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23453\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm\",\"datePublished\":\"2022-12-21T12:51:00+00:00\",\"dateModified\":\"2025-01-27T12:54:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23453\"},\"wordCount\":467,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Biosimilars\",\"Cancer\",\"Mabwell Bioscience\",\"Ophthalmology\",\"Pediatric drugs\",\"SHA: 688062\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23453#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23453\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23453\",\"name\":\"Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-12-21T12:51:00+00:00\",\"dateModified\":\"2025-01-27T12:54:50+00:00\",\"description\":\"China-based Mabwell Bioscience (SHA: 688062) has announced the establishment of a licensing agreement with the Russian pharmaceutical company Binnopharm Group, focused on 9MW0113, 9MW0321, and 9MW0311, Mabwell's biosimilar versions of adalimumab and denosumab. Binnopharm will have exclusive rights to develop, register, manufacture, and market the drugs with a status of a local product in Russia and Eurasian Economic Union countries. Financial details of the agreement were not disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23453#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23453\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23453#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Mabwell Bioscience (SHA: 688062) has announced the establishment of a licensing agreement with the Russian pharmaceutical company Binnopharm Group, focused on 9MW0113, 9MW0321, and 9MW0311, Mabwell's biosimilar versions of adalimumab and denosumab. Binnopharm will have exclusive rights to develop, register, manufacture, and market the drugs with a status of a local product in Russia and Eurasian Economic Union countries. Financial details of the agreement were not disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23453","og_locale":"en_US","og_type":"article","og_title":"Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23453","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-12-21T12:51:00+00:00","article_modified_time":"2025-01-27T12:54:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23453#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23453"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm","datePublished":"2022-12-21T12:51:00+00:00","dateModified":"2025-01-27T12:54:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23453"},"wordCount":467,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Biosimilars","Cancer","Mabwell Bioscience","Ophthalmology","Pediatric drugs","SHA: 688062"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23453#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23453","url":"https:\/\/flcube.com\/?p=23453","name":"Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-12-21T12:51:00+00:00","dateModified":"2025-01-27T12:54:50+00:00","description":"China-based Mabwell Bioscience (SHA: 688062) has announced the establishment of a licensing agreement with the Russian pharmaceutical company Binnopharm Group, focused on 9MW0113, 9MW0321, and 9MW0311, Mabwell's biosimilar versions of adalimumab and denosumab. Binnopharm will have exclusive rights to develop, register, manufacture, and market the drugs with a status of a local product in Russia and Eurasian Economic Union countries. Financial details of the agreement were not disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23453#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23453"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23453#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23453"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23453\/revisions"}],"predecessor-version":[{"id":23454,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23453\/revisions\/23454"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}